Stay updated on T-VEC + Pembrolizumab in Sarcoma Clinical Trial
Sign up to get notified when there's something new on the T-VEC + Pembrolizumab in Sarcoma Clinical Trial page.

Latest updates to the T-VEC + Pembrolizumab in Sarcoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedThe Publications section now includes a revised explanatory note that publications are automatically filled from PubMed and may not be about the study, and the revision tag was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check18 days agoChange DetectedThe notice about a lapse in government funding that warned information on the page may not be up to date has been removed. The page now displays study details without that operating-status disclaimer.SummaryDifference0.4%

- Check33 days agoChange DetectedResults have been posted on 2025-10-29, including the Best Objective Response Rate (CR + PR) per RECIST 1.1 and the associated results submission dates. The Study Protocol and Statistical Analysis Plan PDF (dated 2024-07-22) was added to Study Documents.SummaryDifference1%

- Check40 days agoChange DetectedTwo screenshots show the same study page with no significant changes to core content (eligibility, interventions, outcomes, or locations); any differences are limited to formatting and date updates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check61 days agoChange Detected- Added a government operating-status notice and links, clarifying NIH Clinical Center operations and where to check updates. - Updated version from v3.1.0 to v3.2.0.SummaryDifference3%

- Check69 days agoChange DetectedCore content status updated: results moved fromSummaryDifference0.2%

Stay in the know with updates to T-VEC + Pembrolizumab in Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the T-VEC + Pembrolizumab in Sarcoma Clinical Trial page.